Long noncoding RNA DNM3OS promotes prostate stromal cells transformation via the miR-29a/29b/COL3A1 and miR-361/TGFβ1 axes

Transforming growth factor-β1 (TGFβ1)-induced differentiation into and the activation of myofibroblasts have been regarded as critical events in benign prostatic hyperplasia (BPH); however, the underlying mechanisms of BPH pathogenesis remain unclear. Microarray profiling, STRING analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotation, and Gene Ontology (GO) enrichment analysis were performed to confirm the candidate genes and long non-coding RNA (lncRNAs) related to BPH. Collagen Type III (COL3A1) was significantly upregulated by TGFβ1 in prostate stromal cells (PrSCs) and might be involved in DNM3OS function in myofibroblasts upon TGFβ1 stimulation. Upon TGFβ1 stimulation, COL3A1 protein was decreased by DNM3OS silencing. miR-29a and miR-29b could directly bind to the DNM3OS and COL3A1 3' untranslated region (UTR)s to negatively regulate their expression, and by serving as a competing endogenous RNAs (ceRNA), DNM3OS competed with COL3A1 for miR-29a/29b binding, therefore counteracting miR-29a/29b-mediated COL3A1 suppression. The effect of DNM3OS silencing on ECM components and TGFβ1 downstream signaling was similar to that of the TGFβ1 inhibitor SB431542. miR-361 could target DNM3OS and TGFβ1; DNM3OS competed for miR-361 binding to counteract miR-361-mediated TGFβ1 suppression. In conclusion, we identified DNM3OS as a specifically-upregulated lncRNA upon TGFβ1 stimulation in PrSCs; by serving as a ceRNA for the miR-29a/29b cluster and miR-361, DNM3OS eliminated miRNA-mediated suppression of COL3A1 and TGFβ1, thereby promoting TGFβ1-induced PrSC transformation into myofibroblasts.

[1]  A. Günther,et al.  The Long Non-Coding RNA DNM3OS is a Reservoir of FibromiRs with Major Functions in Lung Fibroblast Response to TGF-β and Pulmonary Fibrosis. , 2019, American journal of respiratory and critical care medicine.

[2]  Chengwei Chen,et al.  miR-29a/b cluster suppresses high glucose-induced endothelial-mesenchymal transition in human retinal microvascular endothelial cells by targeting Notch2 , 2019, Experimental and therapeutic medicine.

[3]  Na Liu,et al.  Long noncoding RNA LINC00336 inhibits ferroptosis in lung cancer by functioning as a competing endogenous RNA , 2019, Cell Death & Differentiation.

[4]  Feng-Sheng Wang,et al.  MicroRNA-29a is a key regulon that regulates BRD4 and mitigates liver fibrosis in mice by inhibiting hepatic stellate cell activation , 2019, International journal of medical sciences.

[5]  P. Shi,et al.  microRNA-29a inhibits cardiac fibrosis in Sprague-Dawley rats by downregulating the expression of DNMT3A , 2018, Anatolian journal of cardiology.

[6]  Nanjiang Zhou,et al.  Functional role of a long non-coding RNA LIFR-AS1/miR-29a/TNFAIP3 axis in colorectal cancer resistance to pohotodynamic therapy. , 2018, Biochimica et biophysica acta. Molecular basis of disease.

[7]  Chen Chen,et al.  Integrated analysis of long non-coding RNAs and mRNAs associated with peritendinous fibrosis , 2018, Journal of Advanced Research.

[8]  S. Mowla,et al.  Two long non‐coding RNAs, Prcat17.3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancer , 2018, The Prostate.

[9]  W. Nahas,et al.  The Obstructed Bladder: Expression of Collagen, Matrix Metalloproteinases, Muscarinic Receptors, and Angiogenic and Neurotrophic Factors in Patients With Benign Prostatic Hyperplasia. , 2017, Urology.

[10]  A. Sayad,et al.  Association of ANRIL gene polymorphisms with prostate cancer and benign prostatic hyperplasia in an Iranian population. , 2017, Biomarkers in medicine.

[11]  S. Ghafouri-Fard,et al.  The Role of Long Non-Coding RNAs in Ovarian Cancer , 2017, Iranian biomedical journal.

[12]  Xiao-ming Meng,et al.  Inflammatory macrophages can transdifferentiate into myofibroblasts during renal fibrosis , 2016, Cell Death & Disease.

[13]  A. Sayad,et al.  Comparative expression analysis of hypoxia‐inducible factor‐alpha and its natural occurring antisense in breast cancer tissues and adjacent noncancerous tissues , 2016, Cell biochemistry and function.

[14]  Y. B. Sun,et al.  The origin of renal fibroblasts/myofibroblasts and the signals that trigger fibrosis. , 2016, Differentiation; research in biological diversity.

[15]  S. Ghafouri-Fard,et al.  The Role of Long Non-Coding RNAs in Breast Cancer. , 2016, Archives of Iranian medicine.

[16]  Youhua Liu,et al.  Renal fibrosis in 2015: Understanding the mechanisms of kidney fibrosis , 2016, Nature Reviews Nephrology.

[17]  S. Sengupta,et al.  A Study of Molecular Signals Deregulating Mismatch Repair Genes in Prostate Cancer Compared to Benign Prostatic Hyperplasia , 2015, PloS one.

[18]  M. Mack,et al.  Origin of myofibroblasts and cellular events triggering fibrosis. , 2015, Kidney international.

[19]  Yong-Heng Luo,et al.  Rosiglitazone Inhibits TGF-β 1 Induced Activation of Human Tenon Fibroblasts via p38 Signal Pathway , 2014, PloS one.

[20]  J. Catto,et al.  BPH and prostate cancer risk , 2014, Indian journal of urology : IJU : journal of the Urological Society of India.

[21]  Shaoli Das,et al.  Competing Endogenous RNA: The Key to Posttranscriptional Regulation , 2014, TheScientificWorldJournal.

[22]  J. Macoska,et al.  Prostatic fibrosis, lower urinary tract symptoms, and BPH , 2013, Nature Reviews Urology.

[23]  E. Ricevuto,et al.  Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples. , 2013, International journal of oncology.

[24]  Howard Y. Chang,et al.  Genome regulation by long noncoding RNAs. , 2012, Annual review of biochemistry.

[25]  E. Ingenito,et al.  Age-Dependent Decline in Mouse Lung Regeneration with Loss of Lung Fibroblast Clonogenicity and Increased Myofibroblastic Differentiation , 2011, PloS one.

[26]  Yan Hong,et al.  The differential effects of prostate stromal cells derived from different zones on prostate cancer epithelial cells under the action of sex hormones. , 2011, Asian journal of andrology.

[27]  S. Meran,et al.  Fibroblasts and myofibroblasts in renal fibrosis , 2011, International journal of experimental pathology.

[28]  G. Untergasser,et al.  Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia. , 2010, Endocrinology.

[29]  Min Hyun Cho,et al.  Renal fibrosis , 2010, Korean journal of pediatrics.

[30]  L. Adorini,et al.  Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. , 2009, International journal of andrology.

[31]  Mario Maggi,et al.  Human Benign Prostatic Hyperplasia Stromal Cells As Inducers and Targets of Chronic Immuno-Mediated Inflammation1 , 2009, The Journal of Immunology.

[32]  Takahiro Sato,et al.  Dnm3os, a non‐coding RNA, is required for normal growth and skeletal development in mice , 2008, Developmental dynamics : an official publication of the American Association of Anatomists.

[33]  Yasuhiro Yamamoto,et al.  Differential Effects of Prazosin and Naftopidil on Pelvic Blood Flow and Nitric Oxide Synthase Levels in Spontaneously Hypertensive Rats , 2008, Journal of receptor and signal transduction research.

[34]  A. Sciarra,et al.  Inflammation and chronic prostatic diseases: evidence for a link? , 2007, European urology.

[35]  Kazuhiko Hayashi,et al.  Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. , 2007, RNA.

[36]  K. Williams,et al.  Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. , 2007, Cancer research.

[37]  G. Kramer,et al.  Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? , 2007, European urology.

[38]  Feng Yang,et al.  Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. , 2005, Cancer research.

[39]  D. Loebel,et al.  A conserved noncoding intronic transcript at the mouse Dnm3 locus. , 2005, Genomics.

[40]  Günter Lepperdinger,et al.  Profiling molecular targets of TGF-β1 in prostate fibroblast-to-myofibroblast transdifferentiation , 2005, Mechanisms of Ageing and Development.

[41]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[42]  K. M. Haberstroh,et al.  Alterations in the molecular determinants of bladder compliance at hydrostatic pressures less than 40 cm. H2O. , 2002, The Journal of urology.

[43]  J. Tuxhorn,et al.  Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. , 2002, Cancer research.

[44]  G. Ayala,et al.  Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[46]  B. le Bail,et al.  Myofibroblasts are responsible for collagen synthesis in the stroma of human hepatocellular carcinoma: an in vivo and in vitro study. , 1999, Journal of hepatology.

[47]  D. Rowley.  What Might A Stromal Response Mean to Prostate Cancer Progression? , 1998, Cancer and Metastasis Reviews.

[48]  D. Wiederschain,et al.  Dysregulated proteolytic balance as the basis of excess extracellular matrix in fibrotic disease. , 1997, The American journal of physiology.

[49]  G. Gabbiani,et al.  The biology of the myofibroblast. , 1992, Kidney international.

[50]  H. Stein,et al.  Cellular localization of type I III and IV procollagen gene transcripts in normal and fibrotic human liver. , 1990, The American journal of pathology.

[51]  Jun Zhang,et al.  Cell Biology International , 2019 .

[52]  S. S. Lee,et al.  Urological Survey Benign Prostatic Hyperplasia Re : Association between Benign Prostatic Hyperplasia , Body Mass Index , and Metabolic Syndrome in Chinese Men , 2016 .

[53]  M. Metzker.  Sequencing technologies — the next generation , 2010, Nature Reviews Genetics.

[54]  A. Desmoulière,et al.  Myofibroblastic differentiation and extracellular matrix deposition in early stages of cholestatic fibrosis in rat liver. , 1999, Current topics in pathology. Ergebnisse der Pathologie.

[55]  P. Walsh,et al.  Clinical and experimental studies of benign prostatic hyperplasia. , 1990, The Urologic clinics of North America.

[56]  D. S. Coffey,et al.  Etiology and disease process of benign prostatic hyperplasia , 1989, The Prostate. Supplement.

[57]  J. McNeal.  Origin and evolution of benign prostatic enlargement. , 1978, Investigative urology.